<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medgen</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская генетика</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Genetics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2073-7998</issn><publisher><publisher-name>Publishing House «Genius Media» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1234/XXXX-XXXX-2016-3-12-17</article-id><article-id custom-type="elpub" pub-id-type="custom">medgen-100</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Роль полиморфных локусов генов хемокинов (CCR5, CXCL12 и CCL2) в развитии и рецидивировании рака мочевого пузыря</article-title><trans-title-group xml:lang="en"><trans-title>Role of the chemokines polymorphisms (CCR5, CXCL12, CCL2) in development and recurrence of bladder cancer</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Измайлова</surname><given-names>С. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Izmailova</surname><given-names>S. M.</given-names></name></name-alternatives><email xlink:type="simple">ecolab_203@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ахмадишина</surname><given-names>Л. З.</given-names></name><name name-style="western" xml:lang="en"><surname>Akhmadishina</surname><given-names>L. Z.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Измайлов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Izmailov</surname><given-names>A. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Корытина</surname><given-names>Г. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Korytina</surname><given-names>G. F.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кочетова</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kochetova</surname><given-names>O. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Исхакова</surname><given-names>Г. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Iskhakova</surname><given-names>G. M.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Куватова</surname><given-names>Д. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Izmailova</surname><given-names>S. M.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Измайлов</surname><given-names>А.А. (мл.)</given-names></name><name name-style="western" xml:lang="en"><surname>Izmailov</surname><given-names>A. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Павлов</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Pavlov</surname><given-names>V. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Викторова</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Viktorova</surname><given-names>T. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Башкирский государственный медицинский университет Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Bashkir State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Институт биохимии и генетики Уфимского научного центра Российской академии наук</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Institute of Biochemistry and Genetics</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Башкирский государственный медицинский университет Министерства здравоохранения Российской Федерации; Институт биохимии и генетики Уфимского научного центра Российской академии наук</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Bashkir State Medical University; Institute of Biochemistry and Genetics</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>07</day><month>10</month><year>2016</year></pub-date><volume>15</volume><issue>3</issue><fpage>12</fpage><lpage>17</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Измайлова С.М., Ахмадишина Л.З., Измайлов А.А., Корытина Г.Ф., Кочетова О.В., Исхакова Г.М., Куватова Д.Н., Измайлов А.(., Павлов В.Н., Викторова Т.В., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Измайлова С.М., Ахмадишина Л.З., Измайлов А.А., Корытина Г.Ф., Кочетова О.В., Исхакова Г.М., Куватова Д.Н., Измайлов А.(., Павлов В.Н., Викторова Т.В.</copyright-holder><copyright-holder xml:lang="en">Izmailova S.M., Akhmadishina L.Z., Izmailov A.A., Korytina G.F., Kochetova O.V., Iskhakova G.M., Izmailova S.M., Izmailov A.A., Pavlov V.N., Viktorova T.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.medgen-journal.ru/jour/article/view/100">https://www.medgen-journal.ru/jour/article/view/100</self-uri><abstract><p>Хемокины не только индуцируют хемотаксис и воспалительные и иммунные реакции, но и вносят вклад в прогрессию опухоли. Так, хемокины, секретируемые солидной опухолью либо метастатическими очагами, могут вести себя подобно ростовым факторам и усиливать распространение метастазов и ангиогенез. Проведён анализ ассоциаций полиморфных локусов rs333, rs1801157, rs1024611 генов CCR5, CXCL12, CCL2 соответственно с риском развития рака мочевого пузыря (РМП). Показана протективная роль полиморфного локуса rs1024611 гена CCL2 в развитии РМП.</p></abstract><trans-abstract xml:lang="en"><p>Chemokines not only induce chemotaxis and inflammatory and immune responses, but also contribute to the progression of the tumor, so chemokines secreted by solid tumors or metastatic lesions may behave like growth factors and increase the spread of metastasis and angiogenesis. The association study was conducted for rs333 CCR5, rs1801157 CXCL12, rs1024611 CCL2 polymorphisms with bladder cancer development risk. It was shown protective role of the rs1024611 CCL2 in bladder cancer development.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>рак мочевого пузыря</kwd><kwd>ассоциация</kwd><kwd>генетический полиморфизм</kwd><kwd>хемокины</kwd><kwd>bladder cancer</kwd><kwd>association study</kwd><kwd>gene polymorphism</kwd><kwd>chemokines</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Чиссов ВИ, Старинский ВВ, Петрова ГВ. Злокачественные новообразования в России в 2011 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. - М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, 2013. - 288 с.</mixed-citation><mixed-citation xml:lang="en">Чиссов ВИ, Старинский ВВ, Петрова ГВ. Злокачественные новообразования в России в 2011 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. - М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, 2013. - 288 с.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">European Association of Urology. Guidelines. - 2013 edition. http://www.uroweb.org/nc/guidlanes/online-guidlanes/</mixed-citation><mixed-citation xml:lang="en">European Association of Urology. Guidelines. - 2013 edition. http://www.uroweb.org/nc/guidlanes/online-guidlanes/</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Клишо Е.В., Кондакова И.В., Чойнзонов Е.Л. Матриксные металлопротеиназы в онкогенезе. Сибирский онкологический журнал. 2003; № 2: 62-71.</mixed-citation><mixed-citation xml:lang="en">Клишо Е.В., Кондакова И.В., Чойнзонов Е.Л. Матриксные металлопротеиназы в онкогенезе. Сибирский онкологический журнал. 2003; № 2: 62-71.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Aldinucci D, Colombatti A. The inflammatory chemokine CCL5 and cancer progression. Mediators Inflamm. 2014; 2014:292376. doi: 10.1155/2014/292376.</mixed-citation><mixed-citation xml:lang="en">Aldinucci D, Colombatti A. The inflammatory chemokine CCL5 and cancer progression. Mediators Inflamm. 2014; 2014:292376. doi: 10.1155/2014/292376.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">de Oliveira CE, Oda JM, Losi Guembarovski R. et al. CC chemokine receptor 5: the interface of host immunity and cancer. Dis Markers. 2014. doi: 10.1155/2014/126954.</mixed-citation><mixed-citation xml:lang="en">de Oliveira CE, Oda JM, Losi Guembarovski R. et al. CC chemokine receptor 5: the interface of host immunity and cancer. Dis Markers. 2014. doi: 10.1155/2014/126954.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Rankin SM. Chemokines and adult bone marrow stem cells. Immunol Lett. 2012;145(1-2):47-54.</mixed-citation><mixed-citation xml:lang="en">Rankin SM. Chemokines and adult bone marrow stem cells. Immunol Lett. 2012;145(1-2):47-54.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Yu L, Cecil J, Peng SB. et al. Identification and expression of novel isoforms of human stromal cell-derived factor 1. Gene. 2006; 7(374):174-179.</mixed-citation><mixed-citation xml:lang="en">Yu L, Cecil J, Peng SB. et al. Identification and expression of novel isoforms of human stromal cell-derived factor 1. Gene. 2006; 7(374):174-179.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Burger JA, Tsukada N, Burger M. et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96(8):2655-2663.</mixed-citation><mixed-citation xml:lang="en">Burger JA, Tsukada N, Burger M. et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96(8):2655-2663.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Огарков О.Б., Костюнин К.Ю., Гутникова М.Ю. и др. Влияние полиморфизма -2518 A/G гена моноцитарного хемотаксического белка 1 типа (MCP-1) на морфологические проявления хронического гастрита. Вестник Санкт-Петербургского университета. 2009; Сер. 11; Вып. 2: 48-53.</mixed-citation><mixed-citation xml:lang="en">Огарков О.Б., Костюнин К.Ю., Гутникова М.Ю. и др. Влияние полиморфизма -2518 A/G гена моноцитарного хемотаксического белка 1 типа (MCP-1) на морфологические проявления хронического гастрита. Вестник Санкт-Петербургского университета. 2009; Сер. 11; Вып. 2: 48-53.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Яшин КС, Медяник ИА. Иммунотерапия злокачественных опухолей головного мозга (обзор). Соврем. технол. мед. 2014; №4: 189-200. Научная библиотека Кибер Ленинка: http://cyberleninka.ru/article/ n/immunoterapiya-zlokachestvennyh -opuholey-golovnogo-mozga- obzor#ixzz3ulk3z32A</mixed-citation><mixed-citation xml:lang="en">Яшин КС, Медяник ИА. Иммунотерапия злокачественных опухолей головного мозга (обзор). Соврем. технол. мед. 2014; №4: 189-200. Научная библиотека Кибер Ленинка: http://cyberleninka.ru/article/ n/immunoterapiya-zlokachestvennyh -opuholey-golovnogo-mozga- obzor#ixzz3ulk3z32A</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Solе X, Guinо E, Valls J. et al. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006; 22(15):1928-1929.</mixed-citation><mixed-citation xml:lang="en">Solе X, Guinо E, Valls J. et al. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006; 22(15):1928-1929.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Trebst C, Ransohoff RM. Investigating chemokines and chemokine receptors in patients with multiple sclerosis: opportunities and challenges. Arch. Neurol. 2001; 58:1975-1980.</mixed-citation><mixed-citation xml:lang="en">Trebst C, Ransohoff RM. Investigating chemokines and chemokine receptors in patients with multiple sclerosis: opportunities and challenges. Arch. Neurol. 2001; 58:1975-1980.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Tanyel CR, Cincin ZB, Gokcen-Rohlig B. et al. Effects of genetic variants of CCR5 chemokine receptors on oral squamous cell carcinoma. Genet Mol Res. 2013 Nov; 18;12(4):5714-20.</mixed-citation><mixed-citation xml:lang="en">Tanyel CR, Cincin ZB, Gokcen-Rohlig B. et al. Effects of genetic variants of CCR5 chemokine receptors on oral squamous cell carcinoma. Genet Mol Res. 2013 Nov; 18;12(4):5714-20.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kucukgergin C, Isman FK, Dasdemir S. et al. The role of chemokine and chemokine receptor gene variants on the susceptibility and clinicopathological characteristics of bladder cancer. 2012 Dec 10;511(1):7-11. doi: 10.1016/j.gene.2012.09.011.</mixed-citation><mixed-citation xml:lang="en">Kucukgergin C, Isman FK, Dasdemir S. et al. The role of chemokine and chemokine receptor gene variants on the susceptibility and clinicopathological characteristics of bladder cancer. 2012 Dec 10;511(1):7-11. doi: 10.1016/j.gene.2012.09.011.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Lee YH, Song GG. Association between chemokine receptor 5 delta32 polymorphism and susceptibility to cancer: a meta-analysis. J Recept Signal Transduct Res. 2015 Dec;35(6):509-15. doi: 10.3109/10799893.2014.960934.</mixed-citation><mixed-citation xml:lang="en">Lee YH, Song GG. Association between chemokine receptor 5 delta32 polymorphism and susceptibility to cancer: a meta-analysis. J Recept Signal Transduct Res. 2015 Dec;35(6):509-15. doi: 10.3109/10799893.2014.960934.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Федянин МЮ, Трякин АА, Тюляндин СА. Биологические маркеры эффективности предоперационной химиолучевой терапии местно-распространенного рака прямой кишки. Онкологическая колопроктология. 2013; №4: 10-20.</mixed-citation><mixed-citation xml:lang="en">Федянин МЮ, Трякин АА, Тюляндин СА. Биологические маркеры эффективности предоперационной химиолучевой терапии местно-распространенного рака прямой кишки. Онкологическая колопроктология. 2013; №4: 10-20.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Batsi O, Giannopoulou I, Nesseris I. et al. Immunohistochemical evaluation of CXCL12-CXCR4 axis and VEGFR3 expression in primary urothelial cancer and its recurrence. Anticancer Res. 2014 Jul;34(7):3537-42.</mixed-citation><mixed-citation xml:lang="en">Batsi O, Giannopoulou I, Nesseris I. et al. Immunohistochemical evaluation of CXCL12-CXCR4 axis and VEGFR3 expression in primary urothelial cancer and its recurrence. Anticancer Res. 2014 Jul;34(7):3537-42.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Singh V, Jaiswal PK, Kapoor R. et al. Impact of chemokines CCR5?32, CXCL12G801A, and CXCR2C1208T on bladder cancer susceptibility in north Indian population. Tumour Biol. 2014 May;35(5):4765-72. doi: 10.1007/s13277-014-1624-7.</mixed-citation><mixed-citation xml:lang="en">Singh V, Jaiswal PK, Kapoor R. et al. Impact of chemokines CCR5?32, CXCL12G801A, and CXCR2C1208T on bladder cancer susceptibility in north Indian population. Tumour Biol. 2014 May;35(5):4765-72. doi: 10.1007/s13277-014-1624-7.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Singh V, Srivastava P, Srivastava N. et al. Association of inflammatory chemokine gene CCL2I/D with bladder cancer risk in North Indian population. Mol Biol Rep. 2012 Oct;39(10):9827-34. doi: 10.1007/s11033-012-1849-8.</mixed-citation><mixed-citation xml:lang="en">Singh V, Srivastava P, Srivastava N. et al. Association of inflammatory chemokine gene CCL2I/D with bladder cancer risk in North Indian population. Mol Biol Rep. 2012 Oct;39(10):9827-34. doi: 10.1007/s11033-012-1849-8.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Narter KF, Agachan B, Sozen S. et al. CCR2-64I is a risk factor for development of bladder cancer. Genet Mol Res. 2010 Apr;9(2):685-92. doi: 10.4238/vol9-2gmr829.</mixed-citation><mixed-citation xml:lang="en">Narter KF, Agachan B, Sozen S. et al. CCR2-64I is a risk factor for development of bladder cancer. Genet Mol Res. 2010 Apr;9(2):685-92. doi: 10.4238/vol9-2gmr829.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
